Collagen Stimulators Explained: PLLA, PDLLA, PN, Profhilo and Exosomes Compared

What is a collagen stimulator, and how is it different from collagen injections?

A collagen stimulator is an injectable with a property that prompts the body to make its own collagen; it is not collagen put into the skin [5]. The author of a 2022 review calls this group collagen stimulators and says PLLA filler was the first long-acting one [5].

Among fillers that the body can break down, the same review ranks cross-linked hyaluronic acid first, followed by collagen stimulators [5]. So this group is not the same thing as hyaluronic-acid filler; see [[skin-booster-vs-filler]] for the difference.

In search terms, collagen stimulator often also covers four more groups: PDLLA, PN, stimulating hyaluronic acid and exosomes. This article puts them together because people search them together, but they are not officially one class, and their mechanisms and evidence differ.

Every substance here must be injected by a licensed doctor. This article does not recommend places, prices or techniques.

How many types are there, and how do PLLA, PDLLA, PN, Profhilo and exosomes differ?

People search five main groups, PLLA, PDLLA, PN, stimulating hyaluronic acid and exosomes, which are made of different materials and are thought to stimulate skin in different ways [4][6][8][13][16].

PLLA (poly-L-lactic acid), for example Sculptra, is a biodegradable polymer in particle form. A review explains that the particles cause a controlled inflammatory reaction that prompts fibroblasts to make the body's own collagen [4]. Details: [[sculptra-plla-explained]].

PDLLA (poly-D,L-lactic acid), for example Juvelook from VAIM of South Korea, belongs to the same polymer family as PLLA but has an irregular, non-crystalline structure [6][7]. A review describes studies of it for skin elasticity, wrinkles and scars [6]. Details: [[juvelook-pdlla-explained]].

PN (polynucleotide) and PDRN, for example Rejuran, are polymers made from salmon or trout DNA [8][10]. Expert-opinion authors propose that PN may form a water-holding scaffold in the dermis and may activate fibroblasts, but they say the exact mechanism is still under investigation [10]. Details: [[rejuran-pn-polynucleotide-explained]].

Stimulating hyaluronic acid, for example Profhilo, combines high- and low-molecular-weight hyaluronic acid by a heat process without chemical cross-linking agents [13]. In laboratory studies it increased collagen and elastin expression in skin cells [13]. Details: [[profhilo-explained]].

Exosomes are tiny vesicles that cells release to send signals to other cells [16]. They are used in aesthetics both on the skin and by injection, and most human studies are not randomised [16]. Details: [[exosome-skin-explained]].

Is each substance approved, according to official sources?

Among the sources checked, Sculptra is the only one with a US FDA approval document; for exosomes the FDA says there are no approved products, and the maker of Profhilo says US clinical development is still needed [1][2][14][15]. Approval in one country does not carry over to another, and status can change, so always check the date of the source.

PLLA (Sculptra): the US FDA approved it through the PMA pathway from 3 August 2004 for facial fat loss in people with HIV, extended it on 28 July 2009 to nasolabial folds and other facial wrinkles [3], and added fine cheek wrinkles in April 2023 [1]. The approval covers the indications on the label only [2].

PDLLA (Juvelook): no regulator document that could be opened was found while researching this article, so no status is stated. Ask for the registration number on the product the clinic uses and check it with the Thai FDA (อย.) [17].

PN (Rejuran): the maker says it is a medical device, and its CEO claims it is the only PN-based medical device approved under the EU MDR, which is the maker's own statement [11]. A 2021 Korean news report says South Korea's Ministry of Food and Drug Safety approved the HB Plus version [12]. No US FDA approval document was found in the sources read.

Stimulating HA (Profhilo): an IBSA press release dated 28 July 2026 says Evolus will complete clinical development in line with US regulations, which is needed before the FDA can authorise marketing [14]. By the maker's own account, then, it is not yet authorised for US marketing.

Exosomes: an FDA safety notice dated 6 December 2019 says there are no FDA-approved exosome products and that exosomes used to treat disease in humans are regulated as drugs and biological products [15]. The notice is old, so check the FDA's latest position.

Thailand: no Thai FDA page giving a registration number for these products could be opened, so Thai status is not confirmed for any of them. The Thai FDA's Medical Device Control Division runs a site for checking products [17]. Ask to see the registration number on the box or documents and check it yourself.

How strong is the evidence for each substance?

Evidence is limited for all of them: reviews rate PLLA and PN as low to moderate quality, and most exosome studies are not randomised [4][9][16]. Read each number together with who took part and who wrote the paper.

PLLA: a 2024 systematic review covering 11 randomised trials found 5 at high risk of bias, and its authors concluded that the evidence for facial rejuvenation is low quality [4]. The cheek trial the FDA reviewed was run by the maker and included only 2 Asian participants out of 149 [18]. See [[sculptra-plla-explained]].

PN: a 2024 systematic review covers 9 studies and 219 people, mostly in Korea and Italy, and none scored full marks for quality [9]. A 2026 expert paper has authors who advise or work for the maker of Rejuran, and the writing was funded by the maker [10].

PDLLA: a recent eyelid study of Juvelook was preliminary, in Korean women, with a small sample and no comparison group, as its own authors state [7]. The same paper says no large randomised trial has confirmed that PDLLA lasts longer than hyaluronic-acid fillers [7].

Stimulating HA: a 2024 review summarising Profhilo work has three authors who are employees of the maker IBSA, and the writing was supported by IBSA [13]. This article did not assess independent Profhilo studies.

Exosomes: a 2026 systematic review of 19 studies, mostly not randomised, found better hydration and wrinkles in the short term, but the methods varied widely and follow-up was lacking [16].

What are the risks of collagen-stimulator injections?

Risks differ by substance: lumps under the skin are reported with PLLA and PDLLA, local side effects with PN, and for exosomes the FDA received reports of serious events from unapproved products [2][6][9][15].

PLLA: the Sculptra label warns of nodules and papules that can appear days to months after injection, and warns that if the material enters a blood vessel it can cause blockage, local skin death, vision problems, blindness or stroke, rare but serious [2].

PDLLA: a review lists complications that need managing: granulomas (hard lumps), non-inflammatory nodules and material migration [6].

PN: a 2024 review found no severe side effects in the included studies; what was reported were local effects such as swelling, pain, itching, redness and bruising [9]. The expert-opinion authors say long-term safety data are limited and rare events cannot be excluded [10].

Exosomes: in 2019 the FDA said it had received reports of serious adverse events in patients in Nebraska who were treated with unapproved products marketed as containing exosomes [15]. A 2026 review says most studies reported good safety for topical use, except for individual reports of risk from off-label injection [16].

Choice of substance, area and injector must be judged case by case by a licensed doctor.

What should I ask a doctor before choosing one of these?

Ask which product and registration number will be used, what evidence supports it, what the risks are, and who handles problems afterwards [2][9][15][17]. A brand name and a substance name are not the same thing, so ask the doctor to name the substance and the maker clearly.

To compare these with hyaluronic-acid fillers and skin boosters, read [[skin-booster-vs-filler]] and [[hyaluronic-acid-label]].

Questions to take with you [2][9][15][17]:

• Which substance is it, who makes it, and does the registration number on the box match what the Thai FDA site shows? [17]
• Is the area I want treated within an approved indication, or is it off-label use? [2]
• What evidence supports it, who took part, and do the authors have ties to the maker? [9][10]
• Which risks can happen with this substance, such as lumps or vessel blockage, and what happens if they do? [2][6]
• If it is an exosome product, which regulator approved it, and is there a document? [15]
• Are you a licensed doctor trained on this product?